{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-26-000100","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2026-08-06T11:15:24+00:00","discovered_at":"2026-08-06T11:20:00.387184+00:00","generated_at":"2026-08-06T11:20:21.902468+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immunovant reports Q1 FY2026 net loss of $153.2M; cash $797.8M, pipeline on track","bullets":["Net loss of $153.2M ($0.75/share) vs $120.6M ($0.71/share) YoY; non-GAAP net loss $139.4M.","Cash and equivalents $797.8M as of June 30, 2026, providing runway to potential IMVT-1402 launch in Graves' disease.","R&D expenses $142.6M (GAAP) vs $101.2M YoY, driven by IMVT-1402 clinical trial costs.","Pipeline on track: topline data for D2T RA and CLE in H2 2026; GD and MG in 2027; CIDP and SjD in 2028.","G&A expenses decreased to $17.7M from $26.0M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-26-000100","json":"https://secwatch.observer/filing/0001764013-26-000100.json","markdown":"https://secwatch.observer/filing/0001764013-26-000100.md","text":"https://secwatch.observer/filing/0001764013-26-000100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/0001764013-26-000100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/imvt-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:20:21.902468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}